SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
Description: SR9011 is a trifunctional methacrylate monomer that provides exceptional adhesion to metal substrates. SR9011 is recommended for use in peroxide cured coatings, sealants, and PVC-based plastisols. Usage levels of 5% to 10% by weight are recommended.S...